IGF-I activates the mouse type IIb myosin heavy chain gene

Authors
R. Andrew Shanely, Kevin A. Zwetsloot, Thomas E. Childs, Simon J. Lees, Richard W. Tsika & Frank W. Booth

NO ABSTRACT
IGF-I activates the mouse type IIb myosin heavy chain gene

R. Andrew Shanely,1,7* Kevin A. Zwetsloot,1,6* Thomas E. Childs,1 Simon J. Lees,1 Richard W. Tsika,1,3 and Frank W. Booth1,2,4,5

Departments of 1Biomedical Sciences, 2Medical Pharmacology and Physiology, and 3Biochemistry, 4Dalton Cardiovascular Institute, 5Health Activity Center, and 6Health and Activity Rehabilitation Research and Training Center, University of Missouri-Columbia, Columbia, Missouri; and 7Department of Health, Leisure, and Exercise Science, Appalachian State University, Boone, North Carolina

Shanely RA, Zwetsloot KA, Childs TE, Lees SJ, Tsika RW, Booth FW. IGF-I activates the mouse type IIb myosin heavy chain gene. Am J Physiol Cell Physiol 297: C1019–C1027, 2009. First published August 5, 2009; doi:10.1152/ajpcell.00169.2009.—IGF-I increases skeletal muscle mass, but whether IGF-I increases type IIb myosin heavy chain (MyHC) transcriptional activity is not known. C57BL/6 myotubes were cultured with or without IGF-I to determine whether IGF-I increases type IIb MyHC promoter activity, and if so, what region of the promoter might IGF-I signaling regulate. At differentiation days 3 and 4, IGF-I increased type IIb MyHC mRNA and mouse 3.0-kb type IIb MyHC promoter activity. Deletion construct studies identified a potential IGF-I-responsive region between 1.25 and 1.2 kb of the type IIb MyHC promoter, which contained an exact 6-bp T-cell factor/lymphoid enhancer factor (Tcf/Lef) binding site at position +1206 to +1201. Site-specific mutation of the putative Tcf/Lef binding site reduced IGF-I-induced 1.3-kb type IIb MyHC promoter activity. To identify potential IGF-I signaling molecules, the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY-294022 were both found to markedly attenuate IGF-I activation of the 1.3-kb type IIb MyHC promoter. Downstream signaling of IGF-I can phosphorylate and inactivate GSK-3β, thereby enhancing 13-catenin protein. The GSK-3β inhibitor, LiCl, dramatically enhanced IGF-I induction of the 1.3-kb type IIb MyHC promoter, and constitutively active GSK-3β attenuated IGF-I-induced 1.3-kb type IIb MyHC promoter activity. Finally, IGF-I increased nuclear 13-catenin protein, and small interfering RNA knockdown of 13-catenin attenuated IGF-I-induced 1.3-kb type IIb MyHC promoter activity and type IIb MyHC mRNA. In summary, IGF-I stimulation of C57BL/6 myotubes increases mouse type IIb MyHC promoter activity, likely through signaling of PI3K, GSK-3β, 13-catenin, and a Tcf/Lef binding site at -1,206 to -1,201 bp in the promoter.

Insulin-like growth factor I; C57BL/6 myocytes; 13-catenin

EXOGENOUS IGF-I DELIVERED either through osmotic pumps (1) or genetic overexpression (20) results in greater skeletal muscle mass in rodents. A similar response has been noted on application of IGF-I to cultured myotubes, where larger myotube diameters and higher protein contents have been reported (22, 33). To increase muscle mass, IGF-I would have to increase myosin heavy chain (MyHC) expression, because it is a major contractile protein in skeletal muscle. MyHC has multiple isoforms in limb skeletal muscle (MyHC I, IIa, IIx/d, and IIb), each with its own gene (24). Barton-Davis et al. (3) demonstrated that overexpression of IGF-I for 9 mo in extensor digitorum longus (EDL) muscles (primarily composed of type IIb fibers) prevented muscle atrophy and the loss of type IIb fibers in old mice. In transgenic mice that overexpress IGF-I in skeletal muscle, the cross-sectional diameter of type IIb fibers was increased (20). In addition, Flint et al. (10) demonstrated that IGF-I overexpression in denervated muscle prevents the loss of type IIb MyHC protein. We therefore chose to study whether IGF-I signaling increases type IIb MyHC promoter activity in mouse skeletal muscle. Our notion is that an IGF-I downstream target, such as type IIb MyHC, could serve as a source to identify a potential regulatory site for IGF-I interactions with other genes.

Under steady-state conditions, most agree that MyHC genes are regulated at the transcriptional/pretranslational level (2). Nuclear run-on assays indicate that the type IIb MyHC gene is transcriptionally activated as myoblasts fuse and mature to myotubes in tissue culture (7) and during whole skeletal muscle development (6). These observations have been confirmed and extended by others. Swoap (28) and Wheeler et al. (34) determined that the type IIb MyHC promoter has 35 times greater in vivo transcriptional activity in the rat tibialis anterior muscle [26–46% IIb fibers (9)] than in the slow-twitch soleus [0% IIb fibers (9)]. Furthermore, changes in contractile activity, e.g., muscle training or hindlimb unloading, can alter MyHC phenotype, and these changes at the protein level are preceded by changes at the mRNA level (4, 13, 15). Nonetheless, how IGF-I modulates type IIb MyHC and many other skeletal muscle genes remains unknown. To our knowledge, there are no data at the level of the type IIb MyHC promoter that support a role for IGF-I increasing type IIb MyHC mRNA. Therefore, the purpose of the current study was to investigate whether IGF-I increases type IIb MyHC promoter activity and potential signaling mechanism(s) associated with its increase.

METHODS

Cell culture. All cell culture experiments were performed with C57BL/6 myoblasts (American Type Culture Collection CRL-1722) under standard conditions (37°C and 10% CO2) and maintained at a subconfluent density in growth medium (GM). GM consisted of Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 20% (vol/vol) fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 40 µg/ml gentamicin. Transient transfections were performed using 0.078 pmol of plasmid DNA and Lipofectamine 2000 (Invitrogen) according to the manufacturer’s recommendations in antibiotic-free GM for 6 h. Differentiation was induced 18 h after transfection by replacing the GM with differentiation media [DM; DMEM, 2% (vol/vol) horse serum] or DM + IGF-I (250 ng/ml; PeproTech). DM and DM + IGF-I were replaced every 24 h. Dimethyl sulfoxide (vehicle), lithium chloride [10 mM (21)], wortmannin [100 nM (8)], LY-294002 [10 µM (32)], and rapamycin [1 µg/ml (25)] were purchased from Sigma Chemicals. The constitutively active glycogen...
synthase kinase-313 plasmid, pGSK-3A9 (caGSK-313), was a gift from James R. Woodgett (University of Toronto, Toronto, ON, Canada) (26). The 13-catenin antibody was purchased from Cell Signaling (no. 9581).

Generation of promoter reporter, 5'-deletion constructs, and site-directed mutagenesis. The 2.567-base pair (bp) mouse type IIb MyHC promoter sequence published by Takeda et al. (29), accession number M92099, was used to generate the 3,000-bp (3.0-kb) type IIb MyHC promoter and subsequent constructs as follows. The published sequence was input into the University of California Santa Cruz Genome Bioinformatics database (http://genome.ucsc.edu) (17), and 414 additional bases at the 5'-end were retrieved. Thus, 2,981 bp of the 5'-flanking region (-2,968 bp to +13 bp relative to the transcription start site) of the mouse type IIb MyHC gene were polymerase chain reaction (PCR) amplified from purified bacterial artificial chromosome DNA. Briefly, searching the National Center for Biotechnology Information (NCBI) nucleotide data base revealed that clone RP23-294E23 (accession no. AL596129.27) contains the region of chromosome 11 with the MyHC IIb gene (myh4, GeneID: 17884) and its 5'-flanking region (M92099). The clone and the promoter were aligned via the NCBI Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov) for confi

The bacterial artificial chromosome containing clone RP23-294E23 was purchased from Invitrogen. PCR-based methods using AccuPrime Pfx DNA polymerase (Invitrogen) and primers with engineered Mlu I (5'-primers) and Sma I (3'-primers) restriction endonuclease sites for subsequent ligation were used to amplify the 3,000 bp type IIb MyHC promoter segment. Following restriction endonuclease digestion, the promoter clone was ligated into the multiple cloning site of the pGL3 Basic (Promega) reporter vector driving firefly luciferase expression, termed the 3.0-kb type IIb MyHC promoter reporter. Restriction enzyme digest and automated bidirectional sequencing (University of Missouri-Columbia DNA Core Facility) were used to confirm insert size, PCR fidelity, and insert orientation of the entire 2,981 bp. Nineteen 5'-deletion constructs were made using the 3.0-kb type IIb MyHC promoter construct as the template using primers with engineered Mlu I and Sma I restriction endonuclease sites and annealed to the reporter vector. Each 5'-deletion construct has a numerical designation referring to the 5'-promoter sequence most relative to the transcription start site, and the 3'-end of all constructs ends at +13 relative to the transcription start site.

Site-specific mutations on the 1.3-kb type IIb MyHC promoter were accomplished using the Quick Change II site-directed mutagen-ness kit (Stratagene). Complementary DNA oligos were created changing three bases (-1206, -1204, -1202) from the target sequence in the center of the oligos (underlined in each sequence); forward primer sequence: GAACACTTTCCTTCTGGTCTTTCGCTAACACCTGGGGG; reverse primer sequence: CCCCCAGGTGT-TAGGCTAAAGAAACCGAAGAAAAGTGTC. Mutated plasmids were amplified by PCR, followed by the digestion of template 1.3-kb type IIb MyHC plasmid with Dpn I. Plasmids were transformed and grown up in One Shot Top10 competent cells (Invitrogen) and purified with the Qiagen Plasmid Midi Kit (Qiagen).

Small interfering RNA transfections. To optimize transfection conditions, C2C12 myoblasts were cotransfected with the wild-type 1.3-kb type IIb MyHC promoter (same concentration as previous experiments; 0.078 pmol) and increasing concentrations of either three different small interfering RNA (siRNA) constructs against mouse 13-catenin (s63417; no. 1, s63418; no. 2, and s63419; no. 3), non-targeting, negative control siRNA (NT siRNA; 4390843), or GAPDH- positive control siRNA (4390849), all from Applied Biosystems (AB). Preliminary experiments on 13-catenin siRNA constructs revealed that siRNA construct no. 3 (s63419) was the most effective of the three. Optimization experiments on 13-catenin siRNA construct no. 3 revealed 80% knockdown of 13-catenin mRNA with transfection of 3–9 nM (Fig. 7B); therefore 3 nM 13-catenin siRNA construct no. 3 was used for the remaining siRNA experiments. For type IIb MyHC promoter activity and mRNA experiments with 13-catenin siRNA, C2C12 myoblasts were cotransfected with either the wild-type or mutated 1.3-kb type IIb MyHC promoter and/or either 3 nM 13-catenin siRNA or 25 nM NT siRNA using Lipofectamine 2000. At 24 h posttransfection, cells were washed with PBS and changed to DM or DM + IGF-I (250 ng/ml). Cells were harvested after 3 days of differentiation and analyzed for type IIb MyHC promoter luciferase activity or type IIb MyHC mRNA.

Real-time PCR. Total cellular RNA was isolated from C2C12 myotubes at specified time points (QIAshredder and RNeasy Micro; Qiagen) and reverse transcribed (Superscript III First-Strand Synthesis System; Invitrogen) using random hexamers. Each reaction, performed in duplicate, contained 25 ng cDNA, 250 nM MGB probe, 900 nM primers, and Taqman Universal PCR Master Mix (AB) in a 25-µl volume. An AB Prism 7000 sequence detection system was used for all real-time PCR reactions. Type IIb MyHC primers and probe were designed using Primer Express (AB); forward primer sequence: GAGAGGTGACAGGAGAAATCACAA; reverse primer sequence: TGCAGAATTTATTTCCGTGATATACAC; probe sequence: TGT-
RESULTS AND DISCUSSION

Barton-Davis et al. (3) previously reported that overexpression of IGF-I completely prevents the age-related loss of type IIb muscle fibers in old mouse EDL muscle. In addition, IGF-I has been shown to increase type IIb MyHC protein in denervated skeletal muscle (3, 10). However, mechanisms that might regulate type IIb MyHC expression in response to IGF-I are largely unknown. Since type IIb MyHC expression is transcriptionally regulated in response to thyroid hormones and mechanical stimuli (2), it seemed logical to hypothesize that IGF-I might increase type IIb MyHC promoter activity. Therefore, the purpose of this study was to investigate whether IGF-I increases type IIb MyHC promoter activity using reporter gene assays and, if so, to identify a regulatory element and potential upstream signaling to this element. Using C2C12 muscle cells, we demonstrate, for the first time, that IGF-I increases type IIb MyHC mRNA levels and activity of the type IIb MyHC promoter. Furthermore, these novel findings suggest that IGF-I-induced promoter activity of type IIb MyHC involves GSK-3β, 13-catenin, and a putative Tcf/Lef binding site in the promoter region of the type IIb MyHC gene.

IGF-I induces type IIb MyHC promoter activity. To investigate whether IGF-I increases type IIb MyHC mRNA, we differentiated C2C12 muscle cells with or without IGF-I for 4 days (Fig. 1). Type IIb MyHC mRNA was not detectable in undifferentiated myocytes (data not shown), nor was it detectable after 1 day of differentiation under control or IGF-I conditions (data not shown). In the absence of IGF-I, type IIb MyHC mRNA levels increased 2- and 5-fold at differentiation days 3 and 4, respectively, as compared with day 2 (Fig. 2A). These data are in accordance with a previous study reporting increased levels of type IIb MyHC mRNA during differentiation without added IGF-I (30). However, when IGF-I was added to the differentiation media, type IIb MyHC mRNA levels increased to a greater degree than without IGF-I (12- and 7-fold at days 3 and 4 of differentiation, respectively) (Fig. 2A). Based on our finding that IGF increases type IIb MyHC mRNA and on the fact that mRNA levels are determined by the rates of transcription and/or mRNA stabilization and MyHC gene transcription is a primary regulatory point for MyHC expression (see Ref. 2 for reference), promoter analysis studies were pursued.

To examine whether the IGF-I-induced increases in type IIb MyHC mRNA were due to increased activity of the type IIb MyHC promoter, we constructed a promoter reporter contain-
3-kinase (PI3K)/Akt pathway in skeletal muscle hypertrophy

IGF-I 1.25-kb activity.

length, $P < 0.05$ from control within same promoter

average promoter activity and are reported as the

percentage of control 3-kb type IIb MyHC

promoter. Values are expressed as

of differentiation, PI3K/Akt-GSK-3 signaling to the type IIb MyHC promoter.

Deletion analysis reveals an IGF-I responsive region between -1,250 and -1,200 bp on the type IIb MyHC promoter. To determine the region(s) of IGF-I-induced transcriptional activity in the type IIb MyHC promoter, 5′-deletion constructs were generated from the 3.0-kb type IIb MyHC promoter reporter. Luciferase promoter activity assays revealed three potential IGF-I-responsive regions in the type IIb MyHC promoter: -1,300 to -1,200; -1,100 to -1,000; and -500 to -400 bp (Fig. 3A). Of the three potential IGF-I-responsive regions in the type IIb MyHC promoter, the -1,300- to -1,200-bp deletion produced the largest decrement in IGF-I activation, and therefore the -1,300- to -1,200-bp region was pursued. When an additional 50-bp deletion construct was generated between -1,300 and -1,200 bp (1.25-kb), a significant decrease in IGF-I-induced promoter activity was detected between the 1.25-kb to 1.2-kb constructs, but not between 1.3-kb and 1.25-kb (Fig. 3B), suggesting a potential IGF-I-responsive region between -1,250 and -1,200 bp in the type IIb MyHC promoter.

IGF-I-PI3K/Akt-GSK-3[3 signaling to the type IIb MyHC promoter. IGF-I signaling activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in skeletal muscle hypertrophy (for review see Ref. 12). Downstream signaling from the IGF-I receptor and PI3K involves Akt-directed phosphorylation and inactivation of glycogen synthase kinase-313 (GSK-313) in skeletal muscle cells (8, 32, 33).

To gain insight into potential IGF-I signaling mechanism(s) to the -1,300 to -1,200 bp region of the type IIb MyHC promoter, a pharmacological approach was first undertaken. C2C12 muscle cells were differentiated with or without IGF-I for 3 days; the pharmacological inhibitors for molecules involved in the PI3K signaling cascade were added during the final 24 h. Inhibiting PI3K with wortmannin completely abolished 1.3-kb type IIb MyHC promoter activity (Fig. 4A) and type IIb MyHC mRNA (Fig. 4B) in response to IGF-I. The PI3K inhibitor, LY-294002, and the inhibitor of mammalian target of rapamycin (mTOR; a downstream target of PI3K/Akt signaling), rapamycin, both significantly attenuated type IIb MyHC promoter activity (Fig. 4A) and type IIb MyHC mRNA levels (Fig. 4B) in response to IGF-I, implying that multiple pathways may be involved in signaling to the type IIb MyHC promoter. A possible limitation to our pharmacological approach is that wortmannin, LY-294002, and rapamycin can specifically inhibit transcription and/or translation of the luciferase reporter gene, or have nonspecific effects on general transcription and/or translation. Additionally, it should be emphasized that inhibitors were present in the differentiation media for only the last 24 h; thus, normal expression of trans-activating factors of IGF-I signaling molecules were not impacted by the inhibitors during the initial 48 h of differentiation. These data (Fig. 4, A and B) suggest that the significant increases in type IIb MyHC mRNA (Fig. 2A) and promoter activity by IGF-I (Fig. 2B) that occur between 48 and 72 hrs of differentiation likely require IGF-I activation of PI3K/Akt signaling.
mouse type IIb MyHC promoter. 13-Catenin, a transcriptional coactivator, binds to an NH$_2$-terminal domain of Tcf/Lef facilitating the assembly of multimeric complexes containing transcriptional coactivators, such as CBP/p300, BCL9/LGS and Pygo, which can activate transcription of target genes. Tcf/Lef proteins bind to a conserved DNA sequence, classically known as the Wnt-response element (WRE: C/T-C-T–T- T-G-A/T-A/T) or as referred to here as the Tcf/Lef binding site (14). When canonical Wnt signaling is absent, GSK-3 phosphorlates 13-catenin, targeting it for ubiquitination and degradation by the proteasome, thereby disrupting the formation of these transcriptional complexes (see Refs. 11 and 35 for references). Previously, we reported that IGF-I phosphorylates and inactivates GSK-3 (33). Taken together, these data suggest a possible link between IGF-I/GSK-3 signaling, 13-catenin, and the Tcf/Lef binding element within this region of the type IIb MyHC promoter.

To verify the putative Tcf/Lef binding site’s IGF-I responsiveness, we next performed site-directed mutagenesis on the -1,206 to -1,201 bp region of the 1.3-kb type IIb MyHC promoter.

Fig. 4. Chemical inhibition of the 1.3-kb type IIb MyHC promoter and type IIb MyHC mRNA levels. C2C12 myocytes were harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). Vehicle (DMSO) or the inhibitors wortmannin (WM, 100 nM), LY-294002 (LY, 10 µM), and rapamycin (Rap, 1 µg/ml) were added during the final 24 h of 3 days of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control vehicle. B: type IIb MyHC mRNA levels. Values are expressed as a percentage of control vehicle and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control within same treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle.

Genetic (22) or chemical (33) inhibition of GSK-313 has been demonstrated to induce significant myotube hypertrophy. Thus, we sought to determine whether modulating GSK-313 activity by chemical inhibition or genetic manipulation would alter type IIb MyHC promoter activity. We hypothesized that lithium chloride (LiCl), a noncompetitive inhibitor of GSK-313, would enhance IGF-I-induced activation of the 1.3-kb type IIb MyHC promoter. Indeed, addition of LiCl significantly increased both 1.3-kb type IIb MyHC promoter activity (Fig. 5A) and the levels of type IIb MyHC mRNA (Fig. 5B). Furthermore, when IGF-I and LiCl treatments were combined, the effects on 1.3-kb type IIb MyHC promoter activity were additive, reminiscent of the additive effects of GSK-313 inhibition observed with the insulin-induced hypertrophic response in C2.7 myogenic cells reported by Rochat et al. (21).

Promoter analysis reveals a putative Tcf/Lef binding element and [3-catenin as a potential link between IGF-I/GSK-3 signaling and type IIb MyHC promoter activity. To further investigate the IGF-I-responsive region in the type IIb MyHC promoter at -1,300 to -1,200 bp, MatInspector (http://www.genomatix.de/) (5) was utilized to search this region for possible transcription factor binding sites. The search revealed an exact 6-bp T-cell factor/lymphoid enhancer factor (Tcf/Lef) DNA binding site located between -1,206 and -1,201 bp of the type IIb MyHC promoter. 13-Catenin, a transcriptional coactivator, binds to an NH$_2$-terminal domain of Tcf/Lef facilitating the assembly of multimeric complexes containing transcriptional coactivators, such as CBP/p300, BCL9/LGS and Pygo, which can activate transcription of target genes. Tcf/Lef proteins bind to a conserved DNA sequence, classically known as the Wnt-response element (WRE: C/T-C-T–T- T-G-A/T-A/T) or as referred to here as the Tcf/Lef binding site (14). When canonical Wnt signaling is absent, GSK-3 phosphorlates 13-catenin, targeting it for ubiquitination and degradation by the proteasome, thereby disrupting the formation of these transcriptional complexes (see Refs. 11 and 35 for references). Previously, we reported that IGF-I phosphorylates and inactivates GSK-313 (33). Taken together, these data suggest a possible link between IGF-I/GSK-313 signaling, 13-catenin, and the Tcf/Lef binding element within this region of the type IIb MyHC promoter.

To verify the putative Tcf/Lef binding site’s IGF-I responsiveness, we next performed site-directed mutagenesis on the -1,206 to -1,201 bp region of the 1.3-kb type IIb MyHC promoter.

Fig. 4. Chemical inhibition of the 1.3-kb type IIb MyHC promoter and type IIb MyHC mRNA levels. C2C12 myocytes were harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). Vehicle (DMSO) or the inhibitors wortmannin (WM, 100 nM), LY-294002 (LY, 10 µM), and rapamycin (Rap, 1 µg/ml) were added during the final 24 h of 3 days of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control vehicle. B: type IIb MyHC mRNA levels. Values are expressed as a percentage of control vehicle and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control within same treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle.

Genetic (22) or chemical (33) inhibition of GSK-313 has been demonstrated to induce significant myotube hypertrophy. Thus, we sought to determine whether modulating GSK-313 activity by chemical inhibition or genetic manipulation would alter type IIb MyHC promoter activity. We hypothesized that lithium chloride (LiCl), a noncompetitive inhibitor of GSK-313, would enhance IGF-I-induced activation of the 1.3-kb type IIb MyHC promoter. Indeed, addition of LiCl significantly increased both 1.3-kb type IIb MyHC promoter activity (Fig. 5A) and the levels of type IIb MyHC mRNA (Fig. 5B). Furthermore, when IGF-I and LiCl treatments were combined, the effects on 1.3-kb type IIb MyHC promoter activity were additive, reminiscent of the additive effects of GSK-313 inhibition observed with the insulin-induced hypertrophic response in C2.7 myogenic cells reported by Rochat et al. (21).

Promoter analysis reveals a putative Tcf/Lef binding element and 13-catenin as a potential link between IGF-I/GSK-3 signaling and type IIb MyHC promoter activity. To further investigate the IGF-I-responsive region in the type IIb MyHC promoter at -1,300 to -1,200 bp, MatInspector (http://www.genomatix.de/) (5) was utilized to search this region for possible transcription factor binding sites. The search revealed an exact 6-bp T-cell factor/lymphoid enhancer factor (Tcf/Lef) DNA binding site located between -1,206 and -1,201 bp of the type IIb MyHC promoter.

Fig. 5. Lithium chloride (LiCl) modulation of the 1.3-kb type IIb MyHC promoter and type IIb MyHC mRNA levels. C2C12 myocytes were harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). DMSO (vehicle) or LiCl (10 mM) was added during the final 24 h of 3 days of differentiation. A: 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control vehicle. B: type IIb MyHC mRNA levels. Values are expressed as a percentage of control vehicle and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control within same treatment, #P < 0.05 from control vehicle, $P < 0.05 from IGF-I vehicle.
promoter (Fig. 6A). Site-directed mutagenesis of three bases between -1206 and -1201 resulted in a 31% decrease in IGF-I-induced type IIb MyHC promoter activity (Fig. 6B). These data suggest that a Tcf/Lef binding site at -1206 to -1201 on the type IIb MyHC promoter is functional and, for the first time, we demonstrate an IGF-I-responsive region on the type IIb MyHC promoter.

Next, to further examine the potential linkage of GSK-313 to the type IIb MyHC promoter, we employed a genetic approach to modulate GSK-313 activity in the opposite direction as LiCl. We tested whether constitutively active GSK-313 (caGSK-313) would attenuate the increase in type IIb MyHC promoter activity in response to IGF-I. Overexpression of caGSK-313, in the absence of IGF-I, did not affect 1.3-kb type IIb MyHC promoter activity. However, in the presence of IGF-I, the IGF-I-induced increase in type IIb MyHC promoter activity was significantly attenuated by 41% with caGSK-313 (Fig. 6C), suggesting that IGF-I-induced inactivation of GSK-313 may play an important role in transcriptional activation of type IIb MyHC.

To this point, we have reported that both site-directed mutagenesis of the -1206 to -1201 Tcf/Lef binding site and overexpression of caGSK-313 (Fig. 6, B and C, respectively) each attenuate, but do not completely abolish IGF-I-induced increases in 1.3-kb type IIb MyHC promoter activity. These data suggest that mutation of the Tcf/Lef binding site and overexpression of caGSK-313 have similar effects on inhibiting IGF-I signaling to the type IIb MyHC promoter. Therefore, we were surprised with the finding that combining both the mutant 1.3-kb type IIb MyHC promoter and caGSK-313 together induced further attenuation of 1.3-kb type IIb MyHC promoter activity in response to IGF-I (Fig. 6C).

Cross-species nucleotide sequence comparisons showed 100% conservation of the core nucleotide sequence for Tcf/Lef binding sites in the mouse, rat, human, and chimp type IIb MyHC promoters, despite differences in location across species (Fig. 6D). The 5' and 3'-flanking regions, however, showed less than perfect sequence homology across species. Divergence in core element location and 5'- and 3'-flanking region sequence is thought to allow for different binding factors to interact within the transcriptional complex and is likely to confer developmental-, tissue-, or perturbation-specific responsiveness (18). For example, the proximal MCAT binding site on the 13-MyHC promoter is highly conserved between human and rat; however, sequence divergence of the 5'-flanking region of this MCAT element exerts profound

Fig. 6. IGF-I activation of the wild-type (WT) and mutant (MUT) 1.3-kb type IIb MyHC promoter with or without constitutively active GSK-313. A: schematic of the putative T-cell factor/lymphoid enhancer factor (Tcf/Lef) binding site at -1,206 to -1,201 bp in the WT 1.3-kb type IIb MyHC construct. The conserved Tcf/Lef binding site is underlined, and site-directed mutations are denoted above the original sequence. Luc luciferase. B: C57BL/6J myocytes were transfected with the 1.3-kb WT type IIb MyHC promoter or the mutated 1.3-kb type IIb MyHC promoter and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). Mutation of the conserved Tcf/Lef binding site attenuates IGF-I-induced 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control WT 1.3-kb type IIb MyHC promoter activity and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control WT 1.3-kb promoter, $P < 0.05 from IGF-I WT 1.3-kb promoter. C: C57BL/6J myocytes were cotransfected with the WT 1.3-kb type IIb MyHC promoter and the pGL3 basic empty vector (EV), the WT 1.3-kb type IIb MyHC promoter and constitutively active glycogen synthase kinase-313 (caGSK-313), or the MUT 1.3-kb type IIb MyHC promoter and caGSK-313, then harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I). caGSK-313 attenuates IGF-I-induced 1.3-kb type IIb MyHC promoter activity. Values are expressed as a percentage of control EV WT 1.3-kb type IIb MyHC promoter activity and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control WT 1.3-kb promoter, $P < 0.05 from IGF-I EV WT 1.3-kb promoter. D: nucleotide sequence comparison of Tcf/Lef binding sites in mouse, rat, human, and chimp type IIb MyHC promoters. The published mRNA sequence for type IIb MyHC for each respective species was input into the University of California, Santa Cruz Genome Bioinformatics database, and 3000 bases 5' to the transcription start site were retrieved and analyzed for Tcf/Lef binding site and flanking region homology. The following genome assemblies were used for retrieval of genomic DNA sequences: mouse - July 2007 (mm9); rat - November 2004 (rn4); human - March 2006 (hg18); and chimp - March 2006 (panTro2). The core Tcf/Lef binding site (boxed) is conserved across these species, and the flanking region sequence homology is indicated by gray shading.
myocytes were transfected with either 3 nM IGF-I (IGF-I) and reported as average ± SE of 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA. **P < 0.05 from control NT siRNA and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA.

Nonetheless, these data demonstrate for the first time that transcriptional activation of the mouse type IIb MyHC promoter in response to IGF-I occurs, in part, through components of a Tcf/Lef signaling network. Recently, Schakman et al. (23) reported that Akt, GSK-3\text{\textsuperscript{13}}, and 13-catenin signaling plays a critical role in the anti-atrophic action of IGF-I in skeletal muscle atrophy caused by glucocorticoids. Concurrently, we were investigating whether the Tcf/Lef binding site and 13-catenin play a role in IGF-I-induced type IIb MyHC transcriptional activity. We hypothesized that if IGF-I signaling occurs via the Tcf/Lef binding site on the type IIb MyHC promoter, IGF-I treatment would increase nuclear 13-catenin protein and thus provide further insight into the mechanism by which IGF-I promoted transcriptional activity of type IIb MyHC. Here, for the first time, we show that IGF-I increases nuclear 13-catenin protein 2.8-fold in differentiating C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes, compared with differentiating C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes without IGF-I treatment (Fig. 7A). Recently, Sun and Jin (27) demonstrated that insulin increases nuclear 13-catenin content and induces the nuclear translocation and binding of 13-catenin to two Tcf-binding sites in the human c-Myc gene promoter in intestinal cell lines. Therefore, the possibility exists that increased nuclear 13-catenin protein could interact with Tcf/Lef binding sites on the type IIb MyHC promoter to increase promoter activity of type IIb MyHC in skeletal muscle cells.

Knockdown of 13-catenin blunts IGF-I-induced type IIb MyHC promoter activity and type IIb MyHC mRNA. Initially, we inhibited GSK-3\text{\textsuperscript{13}} using LiCl, which is known to result in stabilization and nuclear translocation of 13-catenin (21), and chronically activated GSK-3\text{\textsuperscript{13}} by genetic mutation in C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes transfected with increasing concentrations of 13-catenin siRNA (16, 31). We inhibited GSK-3\text{\textsuperscript{13}} with siRNA and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC mRNA. Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in 1.3-kb WT type IIb MyHC mRNA. Values are relative to control NT siRNA and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA. **P < 0.05 from control NT siRNA and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA.

Knockdown of 13-catenin blunts IGF-I-induced type IIb MyHC promoter activity and type IIb MyHC mRNA. Initially, we inhibited GSK-3\text{\textsuperscript{13}} using LiCl, which is known to result in stabilization and nuclear translocation of 13-catenin (21), and chronically activated GSK-3\text{\textsuperscript{13}} by genetic mutation in C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes transfected with increasing concentrations of 13-catenin siRNA (s63419; no. 3) or 25 nM nontargeting siRNA (NT siRNA; negative control). Insert: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were transfected with 25 nM NT siRNA, 5 nM GAPDH siRNA (positive control), or 3 nM 13-catenin siRNA, and 13-catenin and GAPDH mRNA were analyzed 2 days after initiation of differentiation. C: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were cotransfected with either 3 nM 13-catenin siRNA or 25 nM NT siRNA and either the WT 1.3-kb type IIb MyHC promoter or the mutated 1.3-kb type IIb MyHC promoter and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC promoter activity. Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in 1.3-kb WT type IIb MyHC promoter activity. Values are expressed as a percentage of control NT siRNA WT and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA. D: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were transfected with either 3 nM 13-catenin siRNA or 25 nM NT siRNA and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC mRNA. Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in type IIb MyHC mRNA. Values are relative to control NT siRNA and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA.

Knockdown of 13-catenin blunts IGF-I-induced type IIb MyHC promoter activity and type IIb MyHC mRNA. Initially, we inhibited GSK-3\text{\textsuperscript{13}} using LiCl, which is known to result in stabilization and nuclear translocation of 13-catenin (21), and chronically activated GSK-3\text{\textsuperscript{13}} by genetic mutation in C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes transfected with increasing concentrations of 13-catenin siRNA (s63419; no. 3) or 25 nM nontargeting siRNA (NT siRNA; negative control). Insert: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were transfected with 25 nM NT siRNA, 5 nM GAPDH siRNA (positive control), or 3 nM 13-catenin siRNA, and 13-catenin and GAPDH mRNA were analyzed 2 days after initiation of differentiation. C: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were cotransfected with either 3 nM 13-catenin siRNA or 25 nM NT siRNA and either the WT 1.3-kb type IIb MyHC promoter or the mutated 1.3-kb type IIb MyHC promoter and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC promoter activity. Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in 1.3-kb WT type IIb MyHC promoter activity. Values are expressed as a percentage of control NT siRNA WT and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA. D: C\text{\textsubscript{2}}C\text{\textsubscript{12}} myocytes were transfected with either 3 nM 13-catenin siRNA or 25 nM NT siRNA and harvested after 3 days of differentiation in DM (control) or DM with 250 ng/ml IGF-I (IGF-I) for the analysis of type IIb MyHC mRNA. Knockdown of 13-catenin with siRNA attenuates IGF-I-induced increases in type IIb MyHC mRNA. Values are relative to control NT siRNA and are reported as the average ± SE of n = 4 wells/group. *P < 0.05 from control NT siRNA, $P < 0.05 from IGF-I NT siRNA.
myocytes, resulting in opposing effects on IGF-I-induced transcriptional activity of type IIB MyHC. In addition, we showed that mutation of the Tcf/Lef binding site attenuated 1.3-kb type IIB MyHC promoter activity. These experiments demonstrate that GSK-313 and the Tcf/Lef binding site at -1,206 to -1,201 bp in the type IIB MyHC promoter play important roles in IGF-I-induced increases in type IIB MyHC transcriptional activity. However, the link that connects these two separate findings has yet to be described. Therefore, we sought to determine whether 13-catenin is involved in IGF-I-induced increases in type IIB MyHC transcriptional activity.

On that note, we pursued attenuation of 13-catenin expression using siRNA technology. Optimization experiments on 13-catenin siRNA revealed 80% knockdown of 13-catenin mRNA with transfection of 3–30 nM 13-catenin siRNA (Fig. 7B). Furthermore, transfection of positive control GAPDH siRNA attenuated GAPDH mRNA levels by 50% but did not affect 13-catenin mRNA and vice versa (Fig. 7B, inset). Moreover, when 13-catenin expression was knocked down using siRNA, IGF-I-induced 1.3-kb type IIB MyHC promoter activity was attenuated 50% (Fig. 7C). Moreover, no further attenuation of IGF-I-induced 1.3-kb type IIB MyHC promoter activity occurred with either mutation of the Tcf/Lef binding site on the type IIB MyHC promoter, or with a combination of 13-catenin siRNA and mutation of the Tcf/Lef binding site. Furthermore, knockdown of 13-catenin using siRNA showed similar attenuation of IGF-I-induced increases in type IIB MyHC mRNA (Fig. 7D). These results confirm the involvement of 13-catenin in IGF-I signaling to the Tcf/Lef binding site at -1,206 to -1,201 bp in the mouse type IIB MyHC promoter in differentiating C2C12 myocytes.

In summary, our data are the first to demonstrate that IGF-I increases 1) type IIB MyHC mRNA levels, 2) transcriptional activity of the mouse type IIB MyHC promoter, and 3) nuclear levels of 13-catenin protein in differentiating C2C12 myocytes. We also utilized the conserved Tcf/Lef binding site at -1,206 to -1,201 bp in the type IIB MyHC promoter as a tool to explore potential signaling mechanism(s) involved in IGF-I-induced type IIB MyHC transcriptional activation. Our data suggest that transcriptional activation of type IIB MyHC in response to IGF-I occurs, in part, through GSK-313 inactivation, nuclear translocation of 13-catenin protein, and an intact Tcf/Lef binding site on the mouse type IIB MyHC promoter. These data provide valuable insight into how IGF-I modulates the complex regulatory mechanisms of type IIB MyHC gene expression and present a novel mechanism by which IGF-I may regulate transcriptional activity of other genes involved in muscle hypertrophy. Furthermore, these findings could prove valuable as a guide in searching for additional IGF-I-induced Tcf/Lef-dependent genes in skeletal muscle, other than type IIB myosin heavy chain.

GRANTS

This work was supported by National Institutes of Health (NIH) Grant AR-051640 (to R. A. Shanely), Fellow of the Health and Activity Rehabilitation Research and Training Center (to K. A. Zwetsloot), NIH Grant AG-18780 (to F. W. Booth), and generous gifts (to F. W. Booth).

REFERENCES


